MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
Abstract Background Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non‐small cell lung cancer (NSCLC) with ROS1 gene rearrangement. However, its efficacy is limited by tolerance and acquired resistance, the mechanisms of which are not fully understood. Th...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2023-03-01
|
| Serie: | Cancer Medicine |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/cam4.5342 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|